Le Lézard
Classified in: Health
Subjects: CALENDAR OF EVENTS, Conference Calls/ Webcasts

Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days


VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Stifel 2024 Virtual CNS Days event.

Company Fireside Chat Presentation Details:
 
Date:Tuesday, March 19, 2024
  
Time:12:30-12:55 PM Eastern Time
  
Webcast:Register here
  
Presenters: Sherry Aulin, Chief Financial Officer
 Chris Von Seggern, Chief Commercial Officer
  

A live webcast of the company presentation will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. For more information, please visit www.xenon-pharma.com.

"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
[email protected]

For Media:
Jodi Regts
Xenon Corporate Affairs
(604) 484-3353
[email protected]



These press releases may also interest you

at 09:05
Smart Meter Introduces World's First Cellular-Enabled Glucose Meter with Notifications and Multi-Language Capabilities
Smart Meter, the leading supplier of Cellular Remote Patient Monitoring (RPM)tm solutions, has introduced a new version of the iGlucose, its patented cellular-connected glucose meter used by over 200,000 people with diabetes since 2019. The...

at 09:00
Ministers Anandasangaree, Hajdu, Vandal, and Ien issue statement on Red Dress Day 2024
Today, the Honourable Gary Anandasangaree, Minister of Crown-Indigenous Relations; the Honourable Patty Hajdu, Minister of Indigenous Services and Minister responsible for FedNor; the Honourable Dan Vandal, Minister of Northern Affairs; and the...

at 08:05
Pushing the Boundaries of Neuroscience with GE HealthCare's SIGNA MAGNUS
GE HealthCare today unveiled SIGNA MAGNUS, an FDA 510(k) pending head-only magnetic resonance (MR) scanner designed to explore advancements in neuroscience, which have been restricted by the performance limitations of conventional whole-body MR...

at 07:00
2024 National Hospice Palliative Care Week 2024 - Palliative Care Means Living Well: Let's Talk About it!
To mark National Hospice Palliative Care Week, the Quebec Coalition for Palliative Care Access (the Coalition) is proud to celebrate the positive impact of palliative care on the well-being of people with life-limiting illness. Palliative care is...

at 06:00
Brazilian Doctor Ushering in New Era of Medical Technology for Treating Cancer and Seeks to Bring Proton Therapy to Brazil
A native born and trained Brazilian oncologist is in the forefront of a new era in the treatment of cancer patients with cutting edge proton therapy medical technology developed in Israel by P-Cure. "It is my dream to be able to bring the P-Cure...

4 mai 2024
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...

More news about Health...


News published on and distributed by: